Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer’s disease

Kuroda, Atsushi; Setoguchi, Manabu; Uchino, Yasushi; Nagata, Kazuya; Hokonohara, Daisuke

doi:10.1111/ggi.13275

Cited by 13 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, rivastigmine, which has dual inhibitory effects on acetylcholinesterase and butyrylcholinesterase, could improve appetite. 28 Although psychotropic medications, such as major tranquilizers and antidepressants, temporarily increase appetite, the present results showed that their use in persons with AD was positively correlated with poor appetite. This might be because the incidence of adverse events due to psychotropic drugs increases with advancing dementia, and excessive sedation and induction of somnolence due to the use of psychotropic drugs occurs in persons with AD.…”

Section: Discussionmentioning

confidence: 42%

See 1 more Smart Citation

Factors affecting the appetites of persons with Alzheimer's disease and mild cognitive impairment

Suma

Watanabe

Hirano

et al. 2018

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 42%

“…This might be due to an improvement of apathy. Also, rivastigmine, which has dual inhibitory effects on acetylcholinesterase and butyrylcholinesterase, could improve appetite …”

Section: Discussionmentioning

confidence: 99%

Factors affecting the appetites of persons with Alzheimer's disease and mild cognitive impairment

Suma

Watanabe

Hirano

et al. 2018

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

“…; Table ). One potential underlying mechanism for this might be that rivastigmine suppresses the degradation of plasma ghrelin by inhibiting plasma BuChE . Ghrelin is a gastrointestinal tract hormone known to increase appetite .…”

Section: Discussionmentioning

confidence: 99%

“…One potential underlying mechanism for this might be that rivastigmine suppresses the degradation of plasma ghrelin by inhibiting plasma BuChE. 23 Ghrelin is a gastrointestinal tract hormone 5 known to increase appetite. 6,7 Further potential mechanisms for this improvement of appetite in patients with AD might be both the inflammatory effects of ChEI in cholinergic pathways, and their ability to improve smell and taste perception by increasing the acetylcholine concentration in olfactory mucosa and taste buds, respectively.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study

Tsuno

Mori

Ishikawa

et al. 2019

Geriatrics Gerontology Int

View full text Add to dashboard Cite

AimMost patients with Alzheimer's disease (AD) experience poor food intake and/or loss of appetite, which accelerates cognitive impairment. Several reports have shown that rivastigmine improves appetite in AD patients. The present study investigated the efficacy of a rivastigmine transdermal patch for the treatment of low food intake in AD patients.MethodsAD patients, recruited through the Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study, were recognized as experiencing either a loss of appetite or poor food intake. A rivastigmine transdermal patch was administered to study participants for 16 weeks. Patients’ food intake, bodyweight, Mini‐Mental State Examination scores and any adverse events were recorded.ResultsA total of 38 patients with AD (age 86.2 ± 5.4 years) were examined. Their mean Mini‐Mental State Examination score was 10.1 ± 7.0 at baseline. A significant increase in food intake amount (54.9 ± 98.0 g, P < 0.01) and food intake ratio (9.3% ± 17.6%, P < 0.01) was observed by week 1, improvements that were maintained throughout the study duration. A multiple linear regression analysis showed that no independent variables were significantly associated with changes in food intake amount or ratio. Patients in the higher Mini‐Mental State Examination subgroup showed a trend change in food intake amount, although this did not reach statistical significance (P = 0.07).ConclusionsThe present study suggests that a rivastigmine transdermal patch might improve poor food intake or loss of appetite in patients with AD. Geriatr Gerontol Int 2019; 19: 571–576.

show abstract

“…Galantamine-induced adiponectin augmentation and HOMA-IR amelioration have been reported so far in one study in young adults with metabolic syndrome within 4 weeks [ 165 ]. On the contrary, rivastigmine, capable also of inhibiting the ghrelin degrading enzyme butyrylcholine esterase, has a direct effect on appetite and the prevention of weight loss, without affecting leptin levels [ 166 , 167 ].…”

Section: Energy Balance Micronutrient Deficiencies and Adipokinesmentioning

confidence: 99%

Appetite, Metabolism and Hormonal Regulation in Normal Ageing and Dementia

Nifli

2018

Diseases

View full text Add to dashboard Cite

Feeding and nutrition follow the growth trajectory of the course of life. The profound physiological changes that human body experiences during ageing affect separate aspects of food intake, from tastant perception to satiety. Concurrent morbidities, such as neurodegeneration, as seen in dementia, and metabolic syndrome, may further shape nutritional behaviours, status and adequacy. In an effort to fill the gap between the exhausting basic research and the actual needs of professionals caring for the exponentially expanding ageing population, the current review addresses major factors relevant to appetite and eating disturbances. Does age alter the perception of food modalities? Is food generally still perceived as alluring and delicious with age? Is there an interplay between ageing, cognitive decline, and malnutrition? What tools can we adopt for proper and timely monitoring? Finally, what anatomical and pathophysiological evidence exists to support a hypothesis of central regulation of metabolic perturbations in normal and accelerated cognitive impairment, and how can we benefit from it in health practice?

show abstract

Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer’s disease

Abstract: The present study suggests that rivastigmine might improve appetite in mild-to-moderate Alzheimer's disease patients by suppressing degradation of plasma active ghrelin through the inhibition of plasma butyrylcholine esterase. Geriatr Gerontol Int 2018; 18: 886-891.

Cited by 13 publications

References 21 publications

Factors affecting the appetites of persons with Alzheimer's disease and mild cognitive impairment

Factors affecting the appetites of persons with Alzheimer's disease and mild cognitive impairment

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study

Appetite, Metabolism and Hormonal Regulation in Normal Ageing and Dementia

Contact Info

Product

Resources

About